
David H Aggen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9078686/publications.pdf Version: 2024-02-01



DAVID H ACCEN

#	Article	IF	CITATIONS
1	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell, 2021, 184, 2988-3005.e16.	28.9	166
2	Bismuth compounds in organic synthesis. Bismuth nitrate catalyzed chemoselective synthesis of acylals from aromatic aldehydes. Tetrahedron, 2004, 60, 3675-3679.	1.9	103
3	A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncolmmunology, 2012, 1, 863-873.	4.6	84
4	Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clinical Cancer Research, 2021, 27, 608-621.	7.0	73
5	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology, 2022, 40, 2333-2341.	1.6	72
6	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
7	Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood, 2013, 122, 348-356.	1.4	61
8	Engineering higher affinity T cell receptors using a T cell display system. Journal of Immunological Methods, 2008, 339, 175-184.	1.4	57
9	Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain $V\hat{I}^2$ fragments. Molecular Immunology, 2009, 46, 902-916.	2.2	51
10	Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. Gene Therapy, 2012, 19, 365-374.	4.5	44
11	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 2022, 40, 1312-1322.	1.6	42
12	Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Engineering, Design and Selection, 2011, 24, 361-372.	2.1	37
13	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. Clinical Cancer Research, 2020, 26, 2087-2095.	7.0	35
14	A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunology, Immunotherapy, 2014, 63, 1163-1176.	4.2	34
15	Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro. Nature Biotechnology, 2017, 35, 1188-1195.	17.5	33
16	T Cell Receptor Engineering. Methods in Enzymology, 2012, 503, 189-222.	1.0	23
17	A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. Seminars in Oncology, 2019, 46, 351-361.	2.2	15
18	Opposite Effects of Endogenous Peptide–MHC Class I on T Cell Activity in the Presence and Absence of CD8. Journal of Immunology, 2011, 186, 5193-5200.	0.8	11

#	Article	IF	CITATIONS
19	Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. Prostate, 2020, 80, 336-344.	2.3	7
20	Bismuth Compounds in Organic Synthesis. Bismuth Nitrate Catalyzed Chemoselective Synthesis of Acylals from Aromatic Aldehydes ChemInform, 2004, 35, no.	0.0	0